Summary.-The superiority of intra-arterial infusion with methotrexate (MTX) over its systemic use in the treatment of head and neck tumours is still being questioned. A model in the rat, suitable for intra-arterial administration of MTX could be constructed. In this model 3 schedules have been investigated: (1) 7 days continuous intra-arterial infusion with MTX; (2) the same schedule combined with leucovorin (CF) 6-hourly intraperitoneally (i.p.) after Sullivan et al. (1959); (3) intermittent administration of MTX 2 x 24 h intra-arterial infusion on Day 1 and 4, while on Day 2, 3, 5, 6 and 7 the catheter is kept open by the continuous intra-arterial infusion of saline. For all the three schedules intra-arterial MTX proved to be superior to its systemic use.
INTRA-ARTERIAL infusion chemotherapy has been carried out in the Antoni van Leeuwenhoek Hospital (Amsterdam) since 1964 as a planned adjuvant to radiotherapy and/or surgery in far advanced head and neck cancer (Snow and Sindram, 1973) . Methotrexate was used in the majority of cases. In recent years the superioritv of intra-arterial administration of cytotoxic drugs over their systemic use has been questioned. Clinical evaluation up till now has not been possible due to the small number of patients treated in each separate centre and also to the lack of standardization of drug schedules. It therefore seemed important to get further information from animal experimental work. The following questions were posed: (1) Is it possible to set up an animal model suitable for continuous intra-arterial infusion of methotrexate (MTX); (2) In this model, is the anti-tumour effect of regional continuous intra-arterial infusion of MTX superior to that of the continuous systemic administration thereof; (3) Also, in an intermittent dose schedule, is the antitumour effect of regional intra-arterial infusion of MTX superior to that of systemic administration?
Until now there has been no success in the development of such a model for various reasons. In large animals such as monkeys and dogs, no transplantable tumours are available in inbred strains. The same holds true for the rabbit. Therefore only small animals like mice and rats remain. These are easy to handle and numerous transplantable tumours are available in inbred strains. However, these small animals present 2 major problems. First, the blood vessels are very small, so that catheterization of the analogous artery used in manexternal carotid artery is not practical. Secondly, there is the problem of catheter fixation, which has to be done in such a way that the animal cannot break the infusion system, yet still retains a certain amount of mobility.
MATERIALS AND METHODS
In the following model for intra-arterial infusion in the rat these problems have been solved. Under general anaesthesia the common carotid artery on one side is ligated In the case of intraperitoneal (i.p.) injections, a second stainless steel tube has been attached in the same way as the other one. The polyethylene catheter from this tube is led subcutaneously into the peritoneal cavity. A tobacco sack ligature in the abdominal wall around the catheter has proved to be an efficient means of fixation of the catheter and to give protection from infection.
In the case of intermittent intra-arterial MTX infusion on Day 1 and Day 4, the catheter has been kept open by continuous saline infusion on Day 2, 3, 5, 6 and 7. The tumour we used is the transplantable R-1 rhabdomyosarcoma, which arose in 1962 in the mandible of an irradiated rat. This tumour was kindly supplied by Professor G. W. Barendsen, Radiobiologic Institute, Rijswijk, Holland. A standardized piece of tumour tissue is implanted in the front margin of each ear in male (WAG x BN) Fl hybrid rats of about 250 g body weight.
One of these tumours is infused locally with MTX while the other tumour serves as a control for the systemic effects. The advantage of this model is that we always compare the anti-tumour effects of intraarterial and systemic MTX in the same animal, and therefore always at the same level of toxicity. Tumour size was measured in 3 dimensions and the product was used as a parameter of tumour volume.
At the beginning of infusion these volumes were between 200 and 400 mm3. The tumour is non-sensitive to i.p. injections of MTX (Franchi, Moretti and Garattini, 1970) . This very resistant tumour has been chosen because of the advantage that volumes can always be measured accurately, and a further consequence of this choice is that cures cannot be expected.
RESULTS
First schedule: 7 days continuous intraarterial infusion of MTX
In preliminary experiments, the animals tolerated the saline infusion very well and also some anti-tumour effects of MTX were noticed. Some animals died after a dose of 0 20 mg/kg/day given continuously for 5 days. We decided to extend the experiments to a 7-day period. The results of 0-14, 0-20 In preliminary experiments, a dose range of 0-28-0-80 mg MTX/kg/day resulted in mortality and tumour volume decrease. Further experiments have been carried out at a dose level of 0*50 mg MTX/kg/day for a total of twice this dose, 1.00 mg MTX/kg in 1 week of infusion. The anti-tumour effect after this dose (9 animals), relative to the saline controls, was a mean tumour volume decrease to 51% on the infusion side and no significant difference on the systemic side. Hence, for this intermittent MTX schedule as well, the antitumour effect of regional intra-arterial MTX is superior to its systemic administration. There was no mortality whereas a similar anti-tumour effect with continuous MTX was observed only at a dose of about the LD50 level. Hence, the intermittent MTX schedule is probably better, and certainly not worse than the continuous schedules for MTX alone and MTX + CF.
DISCUSSION
For all schedules, the anti-tumour effect on the infusion side was always superior to that on the systemic side. Moreover, the intermittent schedule is probably better than the 2 continuous schedules.
In clinical studies, intra-arterial infusion of MTX has always been applied in a continuous schedule with a mean remission rate of 53% reported in recent publications (Bilder and Hornova, 1970; Couture and Deschenes, 1972; Desprez et al., 1972; Freckmann, 1972; Snow and Sindram, 1973) .
Systemically, however, MTX has been applied in head and neck cancer both as monthly 5-day courses, with a mean remission rate of 28% (Huseby and Downing, 1962; Papac, 1963; Hellman, Lanotti and Bertino, 1964; Andrews and Wilson, 1967; Sullivan et al., 1967) and intermittently as intravenous injections, weekly or every 4th day, or 24-48 h intravenous infusions followed by leucovorin rescue, with a mean remission rate of respectively 42% and 43% (Papac, Lefkowitz and Bertino, 1967; Lane et al., 1968; Leone, Albala and Rege, 1968; Healy, Moriarty and Maddock, 1971; Priestman, 1973; Lefkowitz, Papac and Bertino, 1967; Mitchell et al., 1968; Capizzi et al., 1970; Levitt et al., 1972) .
The results from the experiments and the data from the mentioned publications (Goldin et al., 1955 (Goldin et al., , 1966 the therapeutic effect of simultaneous MTX + CF was worse than that of MTX alone. However, when CF was administrated 12-24 h after MTX, the combination proved to be better than MTX alone. The results of Bagshawe (1969) agree with this. He obtained better results if CF, in combination with continuous MTX infusion, was given only twice daily than when it was given 3 or 4 times daily. AITX + 1.2-hourly i.m. CF was at least as effective as MTX alone, but less toxic. The above suggests that the effectiveness of MTX + CF in treatment of head and neck cancer might be increased by changing the schedule for the antidote CF from 6-hourly into 12-hourly i.m.
For all schedules, the anti-tumour effect on the infusion side was superior to that on the systemic side. Moreover, the intermittent schedule is probably better than the 2 continuous schedules. Of the 2 continuous schedules, the combination MTX and CF was no better than MTX alone and probably even worse.
These results and data in the literature suggest that for clinical application: (1) the best results in selected patients might be obtained by combining both principles: regional intra-arterial infusion and intermittent administration, hence with fractionated intra-arterial infusions or injections; (2) the effectiveness of MTX + CF in the treatment of head and neck cancer might be increased by changing the schedule for the antidote CF from 6-hourly to 12-hourly i.m.
